Quintrio
Home

PHARMACEUTICAL PREPARATIONS

KALA BIO, Inc. Common Stock

KALA

Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $3.42 – $3.76
Volume 9,715
Market cap $2M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.47M
Price / earnings
—
Price / book
0.27×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.11×

Profitability

Earnings per share
-$15.64
Return on assets
-95.26%
Return on equity
-111.46%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
6.88×
Quick ratio
6.88×
Cash ratio
0.15×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$19.86M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for KALA, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$1.66M$1.74M$9.86M$4.53M$4.64M$4.59M$4.2M$4.4M
Research and development$59K$61K$366K$6.13M$6.23M$6.06M$5.26M$5.17M
Total operating expenses$1.72M$1.8M$10.23M$7.24M$11.03M$10.67M$9.46M$9.99M
Operating income-$1.72M-$1.8M-$10.23M-$7.24M-$11.03M-$10.67M-$9.46M-$9.99M
Interest expense$0$0-$141K-$963K-$1.08M-$1.09M-$1.39M-$1.48M
Income before taxes-$1.58M-$1.62M$686K-$7.56M-$11.16M-$8.95M-$8.18M-$8.95M
Income taxes$0$0$0$0$0$0$0$0
Net income-$1.58M-$1.62M$686K-$7.56M-$11.16M-$8.95M-$8.18M-$8.95M
Net income attributable to common shareholders-$1.58M-$1.62M$686K-$7.56M-$11.16M-$8.95M-$8.18M-$8.95M
EBITDA-$1.72M-$1.8M-$5.51M-$10.53M-$10.96M-$10.58M-$9.94M-$9.51M
Basic earnings per share-$639.60-$4.20$2.70-$1,605.00-$2,569.20-$2,114.70-$86.72-$2,895.00
Diluted earnings per share-$639.60-$4.20$2.70-$1,605.00-$2,569.20-$2,114.70-$86.72-$2,895.00

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Crude Oil Falls Sharply; Carnival Posts Upbeat Earnings

U.S. stocks traded mixed on Monday, with the Dow Jones falling slightly while NASDAQ rose. Carnival reported strong Q3 earnings, while several biotech stocks experienced significant price drops. Oil prices declined, and U.S. pending home sales surged in August.

Benzinga

Nasdaq Jumps 150 Points; US Pending Home Sales Rise

U.S. stocks traded higher with Nasdaq gaining 150 points. Pending home sales surged 4% in August, marking the sharpest gain in five months. Several biotech companies experienced significant stock price movements.

The Motley Fool

Kala Bio (KALA) Q2 Loss Widens 15%

Clinical-stage biotech Kala Bio reported a Q2 2025 net loss of $1.71 per share, with continued focus on developing KPI-012 for persistent corneal epithelial defects. The company completed patient enrollment in its Phase 2b CHASE trial and expects topline results by September 2025.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Nov 16, 20261-for-30reverse split
May 11, 20261-for-50reverse split
Oct 21, 20221-for-50reverse split
Aug 26, 20221.001-for-1stock dividend